Search research articles
Contact Us
Filters
Showing results (41-50 of 142) with videos related to
Page
of 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2019
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma
Nitika Paudel, Derek Schulze, Ryan D Gentzler, et al.
British Journal of Haematology
|
December 29, 2007
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
Andrew M Evens, Jane N Winter, Nanjiang Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2009
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
Arnold Freedman, Sattva S Neelapu, Craig Nichols, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
Andrew M Evens, Laurie H Sehn, Pedro Farinha, et al.
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Leukemia & Lymphoma
|
April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
Olga Frankfurt, Shuo Ma, Leo Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
Neelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 142) with videos related to
Sort By:
Page
of 15
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2019
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma
Nitika Paudel, Derek Schulze, Ryan D Gentzler, et al.
British Journal of Haematology
|
December 29, 2007
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
Andrew M Evens, Jane N Winter, Nanjiang Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2009
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
Arnold Freedman, Sattva S Neelapu, Craig Nichols, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
Andrew M Evens, Laurie H Sehn, Pedro Farinha, et al.
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Leukemia & Lymphoma
|
April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
Olga Frankfurt, Shuo Ma, Leo Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
Neelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Page
of 15